S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
NYSE:CRL

Charles River Laboratories International Stock Forecast, Price & News

$375.28
-2.23 (-0.59%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$374.13
$385.11
50-Day Range
$369.98
$458.30
52-Week Range
$226.07
$460.21
Volume
192,276 shs
Average Volume
416,277 shs
Market Capitalization
$18.94 billion
P/E Ratio
48.49
Dividend Yield
N/A
Beta
1.13
30 days | 90 days | 365 days | Advanced Chart
Receive CRL News and Ratings via Email

Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter.


Charles River Laboratories International logo

About Charles River Laboratories International

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support. The Research Models & Services segment comprises of the production and sale of research models, and also offers services designed to support its client's use of research models in screening non-clinical drug candidates. The Discovery & Safety Assessment segment offers discovery and safety assessment services, both regulated and non-regulated, in which it include both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Manufacturing Support segment provides endotoxin and microbial detection, avian vaccine and biologics testing solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
CUSIP
15986410
Employees
18,400
Year Founded
1947

Sales & Book Value

Annual Sales
$2.92 billion
Cash Flow
$12.91 per share
Book Value
$48.19 per share

Profitability

Net Income
$364.30 million
Pretax Margin
14.29%

Debt

Price-To-Earnings

Miscellaneous

Free Float
49,858,000
Market Cap
$18.94 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Today
11/26/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/16/2022

Social Links


MarketRank

Overall MarketRank

2.28 out of 5 stars

Medical Sector

289th out of 1,392 stocks

Commercial Physical Research Industry

4th out of 27 stocks

Analyst Opinion: 3.4Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -












Charles River Laboratories International (NYSE:CRL) Frequently Asked Questions

Is Charles River Laboratories International a buy right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories International in the last twelve months. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Charles River Laboratories International stock.
View analyst ratings for Charles River Laboratories International
or view top-rated stocks.

How has Charles River Laboratories International's stock price been impacted by Coronavirus?

Charles River Laboratories International's stock was trading at $136.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CRL shares have increased by 174.7% and is now trading at $375.28.
View which stocks have been most impacted by COVID-19
.

When is Charles River Laboratories International's next earnings date?

Charles River Laboratories International is scheduled to release its next quarterly earnings announcement on Wednesday, February 16th 2022.
View our earnings forecast for Charles River Laboratories International
.

How were Charles River Laboratories International's earnings last quarter?

Charles River Laboratories International, Inc. (NYSE:CRL) released its quarterly earnings results on Tuesday, November, 2nd. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $2.58 by $0.12. The medical research company had revenue of $895.90 million for the quarter, compared to analyst estimates of $902.03 million. Charles River Laboratories International had a net margin of 11.58% and a trailing twelve-month return on equity of 23.14%. The business's quarterly revenue was up 20.5% compared to the same quarter last year. During the same period in the prior year, the company posted $2.33 earnings per share.
View Charles River Laboratories International's earnings history
.

What guidance has Charles River Laboratories International issued on next quarter's earnings?

Charles River Laboratories International issued an update on its FY 2021 earnings guidance on Wednesday, November, 10th. The company provided earnings per share (EPS) guidance of $10.200-$10.300 for the period, compared to the Thomson Reuters consensus estimate of $10.250. The company issued revenue guidance of $3.49 billion-$3.52 billion, compared to the consensus revenue estimate of $3.56 billion.

What price target have analysts set for CRL?

13 Wall Street analysts have issued 1-year target prices for Charles River Laboratories International's shares. Their forecasts range from $324.00 to $480.00. On average, they expect Charles River Laboratories International's stock price to reach $417.00 in the next twelve months. This suggests a possible upside of 11.1% from the stock's current price.
View analysts' price targets for Charles River Laboratories International
or view top-rated stocks among Wall Street analysts.

Who are Charles River Laboratories International's key executives?

Charles River Laboratories International's management team includes the following people:
  • James C. Foster, Chairman, President & Chief Executive Officer
  • Birgit Girshick, Chief Operating Officer
  • David Ross Smith, Chief Financial Officer & Executive Vice President (LinkedIn Profile)
  • Arthur C. Hubbs, Chief Information Officer & Senior Vice President
  • Barbara j. Patterson, Senior VP-Regulatory Affairs & Compliance

What is James C. Foster's approval rating as Charles River Laboratories International's CEO?

291 employees have rated Charles River Laboratories International CEO James C. Foster on Glassdoor.com. James C. Foster has an approval rating of 75% among Charles River Laboratories International's employees.

What other stocks do shareholders of Charles River Laboratories International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories International investors own include NVIDIA (NVDA), Boeing (BA), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), salesforce.com (CRM), Abbott Laboratories (ABT), Mastercard (MA), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

What is Charles River Laboratories International's stock symbol?

Charles River Laboratories International trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

Who are Charles River Laboratories International's major shareholders?

Charles River Laboratories International's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.08%), Kayne Anderson Rudnick Investment Management LLC (2.94%), Invesco Ltd. (2.91%), Massachusetts Financial Services Co. MA (2.69%), William Blair Investment Management LLC (1.87%) and Geode Capital Management LLC (1.81%). Company insiders that own Charles River Laboratories International stock include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George Massaro, James C Foster, Joseph W Laplume, Michael Gunnar Knell, Richard F Wallman, Robert J Bertolini, Stephen D Chubb, Victoria L Creamer and William D Barbo.
View institutional ownership trends for Charles River Laboratories International
.

Which major investors are selling Charles River Laboratories International stock?

CRL stock was sold by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Mackenzie Financial Corp, TimesSquare Capital Management LLC, Bellevue Group AG, Neuberger Berman Group LLC, Iridian Asset Management LLC CT, Montrusco Bolton Investments Inc., and Massachusetts Financial Services Co. MA. Company insiders that have sold Charles River Laboratories International company stock in the last year include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George Massaro, James C Foster, Joseph W Laplume, Michael Gunnar Knell, Victoria L Creamer, and William D Barbo.
View insider buying and selling activity for Charles River Laboratories International
or view top insider-selling stocks.

Which major investors are buying Charles River Laboratories International stock?

CRL stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., American Century Companies Inc., Eagle Asset Management Inc., Kayne Anderson Rudnick Investment Management LLC, Skandinaviska Enskilda Banken AB publ , KBC Group NV, Arrowstreet Capital Limited Partnership, and Bank of New York Mellon Corp.
View insider buying and selling activity for Charles River Laboratories International
or or view top insider-buying stocks.

How do I buy shares of Charles River Laboratories International?

Shares of CRL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Charles River Laboratories International's stock price today?

One share of CRL stock can currently be purchased for approximately $375.28.

How much money does Charles River Laboratories International make?

Charles River Laboratories International has a market capitalization of $18.94 billion and generates $2.92 billion in revenue each year. The medical research company earns $364.30 million in net income (profit) each year or $7.74 on an earnings per share basis.

How many employees does Charles River Laboratories International have?

Charles River Laboratories International employs 18,400 workers across the globe.

Does Charles River Laboratories International have any subsidiaries?

The following companies are subsidiares of Charles River Laboratories International: 3313290 Nova Scotia Company, 9904140 Canada Inc., Accugenix Inc., Agilux Laboratories, Argenta Discovery 2009 Limited, Ballardvale C.V., Beijing Vital River Laboratory Animal Technology Co. Ltd., BioFocus DPI (Holdings) Ltd., Biological Laboratories Europe Ltd. ("BioLabs"), Blue Stream Laboratories, Brains On-Line, CRL Dutch Holding Company B.V., CRL Group France, CRL Group International France, CRL Holding Germany GmbH, CRL Holding Netherlands B.V., CRL Safety Assessment Inc., Celsis Group Limited, Celsis International, Celsis International B.V., Celsis International GmbH, Celsis International Limited, Celsis Limited, Cerebricon, Chantest, Charles River Detecção Microbiana e de Endotoxina Participações Ltda, Charles River Discovery Research Services Finland, Charles River Discovery Research Services Germany GmbH, Charles River Discovery Research Services Inc., Charles River Discovery Research Services International Inc., Charles River Discovery Research Services UK Limited, Charles River Endotoxin Microbial Detection Europe SAS, Charles River Endotoxin and Microbial Detection Israel, Charles River Endotoxin and Microbial Detection Singapore Pte. Ltd., Charles River Germany GmbH & Co. KG, Charles River Germany Verwaltungs GmbH, Charles River Holdings LLC, Charles River Laboratories Ashland LLC, Charles River Laboratories Asia Holdings Limited, Charles River Laboratories Australia Pty. Ltd., Charles River Laboratories Belgium SPRL, Charles River Laboratories Cleveland Inc., Charles River Laboratories Copenhagen, Charles River Laboratories Den Bosch B.V., Charles River Laboratories Edinburgh Ltd., Charles River Laboratories España SA, Charles River Laboratories Evreux, Charles River Laboratories France Safety Assessment SAS, Charles River Laboratories France-C.R.L.F. SAS, Charles River Laboratories Germany GmbH, Charles River Laboratories Group, Charles River Laboratories Holding Europe SAS, Charles River Laboratories Holding SAS, Charles River Laboratories Holdings Limited, Charles River Laboratories Hungary, Charles River Laboratories I Delaware Holdings Inc., Charles River Laboratories II Delaware Holdings Inc., Charles River Laboratories Inc., Charles River Laboratories India Private Limited, Charles River Laboratories Ireland Holding Unlimited Company, Charles River Laboratories Ireland Limited, Charles River Laboratories Italia Srl, Charles River Laboratories Japan Inc., Charles River Laboratories Korea, Charles River Laboratories Luxembourg S.a.r.l., Charles River Laboratories Montreal ULC, Charles River Laboratories Poland Sp. Z.o.o., Charles River Laboratories Research Models and Services Germany GmbH, Charles River Laboratories SA France Acquisition SAS, Charles River Laboratories SA France Holdings SAS, Charles River Laboratories SA Japan KK, Charles River Laboratories SA Netherlands Holdings B.V., Charles River Laboratories SA USA Inc., Charles River Laboratories Saint Nazaire, Charles River Laboratories Saint‑Constant S.A., Charles River Microbial Solutions Company (Shanghai) Limited, Charles River Microbial Solutions International Limited, Charles River Nederland B.V., Charles River UK Limited, Charles River ULC, CiToxLAB, Citox Inc., Citoxlab USA LLC, Cognate BioServices, Genetic Models, HemaCare, Inveresk Research, KWS BioTest, KWS BioTest Limited, MPI Research, Molecular Therapeutics, Nastor Investments, NewLab BioQuality AG, Northwest Kinetics, Oncotest, Pathology Associates International Corporation, Piedmont Research Center, Primedica, Retrogenix Limited, River Valley Farms, Saothorlanna Bitheolaiocha Idirnaisiunta Teoranta, Sierra Biomedical, Solvo Biotechnology USA Inc., Solvo Biotechnológiai Zrt, Springborn Laboratories, Sunrise Farms Inc., Systems Pathology Company LLC, Tektagen Inc, Vigene Biosciences Inc., WIL Research, Zhanjiang A&C Biological Ltd., and Zhejiang Vital River Laboratory Animal Technology Co. Ltd..

When was Charles River Laboratories International founded?

Charles River Laboratories International was founded in 1947.

What is Charles River Laboratories International's official website?

The official website for Charles River Laboratories International is www.criver.com.

Where are Charles River Laboratories International's headquarters?

Charles River Laboratories International is headquartered at 251 BALLARDVALE STREET, WILMINGTON MA, 01887.

How can I contact Charles River Laboratories International?

Charles River Laboratories International's mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company can be reached via phone at (781) 222-6000, via email at [email protected], or via fax at 978-988-5665.


This page was last updated on 11/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.